Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BIOR Biora Therapeutics
4.050-0.010-0.25%
Close
02/07 16:00 ET
4.0500.0000.00%
Post Mkt Price 02/07 18:56 ET
High
4.110
Open
4.000
Turnover
2.02M
Low
3.910
Pre Close
4.060
Volume
503.12K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
10 Short Squeeze Candidates To Watch This Week: Getty Images, PaxMedica And This Meme Stock Retailer
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common trait
Biora Therapeutics, Inc. (BIOR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Biora Therapeutics Files Shelf on Behalf of Selling Stockholder Armistice Capital Master Fund
04:18 AM EST, 01/30/2023 (MT Newswires) -- Biora Therapeutics (BIOR) on Friday filed a shelf registration statement for the potential resale of up to 90,000 of its common shares by selling stockholder
Biora Therapeutics Files to Sell 90K Shares of Common Stock for Holders
BBBY, HEXO and ALLO Are Among Pre Market Gainers
MGNI, BIOR and VERV Are Among After Hour Movers
Biora Therapeutics' Debt Overview
Over the past three months, shares of Biora Therapeutics Inc. (NASDAQ:BIOR) decreased by 61.54%. When understanding a companies price change over a time period like 3 months, it could be helpful to lo
CORRECTION: On January 19, 2023, Biora Therapeutics Received A Letter From Nasdaq Notifying The Co. That The Co.'s Previously Announced Bid Price Deficiency Had Been Cured And The Co. Was In Compliance With All Applicable Continued Listing Standards
CORRECTION: On January 19, 2023, Biora Therapeutics Received A Letter From Nasdaq Notifying The Co. That The Co.'s Previously Announced Bid Price Deficiency Had Been Cured And The Co. Was In Complianc
KPTI, VRNA and SGH Are Among After Hour Movers
Biora Therapeutics Says On Jan. 19, 2023 Co. Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Biora Therapeutics Says On Jan. 19, 2023 Co. Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Company Overview
More
Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.
CEO： Mr. Aditya P. Mohanty
Market： NASDAQ
Listing Date： 06/19/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet